PAPERZILLA
Crunching Academic Papers into Bite-sized Insights.
About
Sign Out
← Back to papers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer
★
★
★
★
☆
SHARE
Overview
Paper Summary
Conflicts of Interest
Identified Weaknesses
Rating Explanation
Good to know
Topic Hierarchy
File Information
Paper Summary
Paperzilla title
Gene Ranking Reveals Top Prognostic Players in Breast Cancer Chemotherapy
By analyzing gene expression data from thousands of breast cancer samples, this study identified and ranked the genes with the highest prognostic power in two clinically relevant cohorts: estrogen receptor-positive/ERBB2-negative patients treated with chemotherapy and basal breast tumors receiving chemotherapy. This ranking helps prioritize promising biomarker candidates for future research and clinical validation.
Possible Conflicts of Interest
None identified
Identified Weaknesses
Limited Treatment Information
Lack of detailed treatment information, including specific protocols, restricts the depth of analysis and interpretation of chemotherapy response.
Incomplete Clinical Data
The study acknowledges incomplete clinical data for many datasets, limiting the number of samples included in analyses and hindering a comprehensive assessment.
Cohort Specificity
Restricting the analysis to specific cohorts, while necessary for statistical power, may overlook potential biomarkers relevant to other breast cancer subtypes or treatment combinations.
Limited Outcome Measure
The study's focus on relapse-free survival, while clinically relevant, does not fully capture the overall impact of chemotherapy on patient outcomes, such as overall survival or quality of life.
Rating Explanation
This study presents a comprehensive analysis of gene expression data related to breast cancer prognosis, utilizing a large dataset and robust statistical methods. The ranking of genes associated with chemotherapy response in specific cohorts provides a valuable resource for future research and biomarker discovery. While limitations regarding clinical data completeness and treatment information exist, the study's strengths outweigh these weaknesses, warranting a strong rating.
Good to know
This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →
Topic Hierarchy
File Information
Original Title:
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer
File Name:
pmc8339292.pdf
[download]
File Size:
1.06 MB
Uploaded:
July 14, 2025 at 10:44 AM
Privacy:
🌐 Public
© 2025 Paperzilla. All rights reserved.